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Introduction: Adherence is the extent to which a person’s behaviour is consistent with health care recommendations[1]. Adherence to a certain therapeutic regime will determine an illness clinical outcome; indeed, treatment strategies must be sustainable to be successful[2]. But how can we quantitatively measure
adherence? Some consider that good adherent patients are those who carry out about 80 % of the recommended behaviour[1], while others believe that an adherence of 95% is the required standard[3]. Actually, adherence is a multifactorial variable depending upon determinants such as population features and the complexity
of therapeutic regime [4]. However some argue that those taking more pills in a daily basis do not seem to differ in terms of compliance from the ones who take simpler regimens[5].
The fact that complex and expensive antiretroviral therapeutics are currently at use makes it important to acknowledge its efficacy which is highly correlated with adherence. Investigating the compliance to such therapies should be a priority on any clinical setting where HIV patients are followed up[6]. Various methods to
measure adherence have been used such as patient-report adherence; pill count; serum concentration of antiretroviral; assisted medication taking[7]. Each one of these methods has its pros and cons, thus using them isolated seem to lack scientific value[8]. However, and despite its limitation, there is one method which is refill
compliance using pharmacy records very useful in predicting patient behaviour towards their medication[9]. This latter method allows the identification of those individual who will not certainly have successful treatment duo to lack of medication acquisition[10, 11].
Objective: Assessment of HIV patient compliance to antiretroviral therapy based on Pharmacy files.
Methods: This is a six-month longitudinal prospective descriptive study starting in January 2004. Our sample population consisted of HIV patients undergoing antiretroviral therapy, except pregnant women and HIV patient while in haemodialysis, who received medication from the Pharmacy Department of Hospital
Fernando Fonseca during the study’s first month. Hospital Fernando Fonseca is a Public General Hospital within the National Health System Hospital Network. This health unit serves a population of about 600.000 individuals and has approximately 678 inpatients beds.
After a previous pilot project to certificate the quality of this study, the authors and other pharmacists collected data that were gathered in the pharmacy records for each patient. These data included demographic variables (age, race and gender) therapeutic regimens features and refill compliance features (dates of pharmacy
department visits and number of pills obtained in each visit).
Based on refill compliance using pharmacy records we assessed a Continuous Measure of Medication Acquisition (CMA = Cumulative days’ supply obtained /Total days to next fill or end of observation period). This index will ultimately give us the adherence of our population to HIV therapy dispenses. We decided to
include in our project the number of days spent in the hospital ward to increase CMA’s probability to be the actual adherence to antiretroviral therapies.
Data were gathered in the Microsoft Excel 2000 and analysed using the Statistical Package for Social Science 9.0 program.
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Results and Discussion :
In the beginning of 2004 we had roughly 700 patients who carried out their HIV therapies.
During the recruitment period we obtained a sampled population of 522 individuals including 9
patients who started their treatment in this stage.
1.- Demographic Variables
As we can observe in our population, the number of Caucasian individuals is higher (n=336;
64,4%) than the number of non Caucasian (n=186; 35,6%) (Table 1). Equally interesting is the
fact that there seems to be no significant difference between the number of male and female in
the non Caucasian patients.
The majority of our patients, 40,2% (n=210) has between thirty and forty years old
(Graphic 1). A highly proportion of our studied subjects are older than we had previously
thought.
2.- Therapeutic Regimens
The most frequent therapeutic regimens are those which included 2 NRTIs (Nucleoside Reverse
Transcriptase Inhibitors) + 1 NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitors)
(51,3%; n=268) and 2 NRTIs + 1 IP ( Protease Inhibitors) (29,3%; n=153) (Table 2). Some
individuals of our target population use others highly diverse regimens possibilities.
Taking into account the number of pills consumption in a daily basis Table 3 clearly puts
forward that 55,9% (n=292) of our patients consume between tree to six pills per day.
From the analysis of data regarding the number of takings on a daily basis we can verify that
the number of takings was between 1 and 5 takings per day, even though there was a higher
incidence when 2 (30,7%; n=160), 3 (44,4%; n= 232) and 5 (22,0%; n=115) takings per day
were considered (Table 4) .
3.- CMA Index
Approximately 24,5 % (n=128) of our population has a CMA 1 and 23,4% (n= 122) has a
0,99 CMA 0,95 (Graphic 2).
These results are not what we expected according to the previous pilot study results.
Having in mind that CMA is an index obtained from pharmacy refill data, which eventually
allow us to speculate about the adherence to HIV therapies, and that CMA = 1 would mean
supposedly one hundred percent adherence, therefore we can assume that our sampled
population is just 24,5 % absolutely adherent to their antiretroviral therapies.
Data Analysis seems to indicate that there are more male individuals (represented by 33,5% of
the studied population and 53,0% of the sampled male population) having a CMA > 0,95 when
compared to the female individuals (represented by 14,5% of the studied population and 39,1%
of the sampled female population) (Table 5).
As far as race is concern, results seem to demonstrate that there are more Caucasian individuals
(represented by 33,5% of the studied population and 52,1% of the sampled Caucasian
population) having CMA> 0,95 when compared to the non Caucasian individuals (represented by
14,3% of the studied population and 40,3% of the sampled non Caucasian population) (Table
6).
Aging seems to influence adherence. As a matter of fact data displayed give the impression that as
long as age of the studied population is augmenting we verify an accompanying increase in the
percentage of the individuals with CMA 1, if we consider the number of individuals inside each
age group (Table 7).
Having in mind the plausible impact of pill burden over the adherence to HIV medication, results
don’t allow us to declare what we had long thought, that a small number of pills consume per day
would be associated with a slightly elevated CMA Index (Table 9).
Looking into Table 8 we can not state that therapeutic regimen would influence adherence to
HIV therapies.
It is not clear at all whether the number of takings is influent or not in adherence to antiretroviral
therapies (Table 10).
Conclusions: Whether we consider antiretroviral therapeutic regimens or demographic
features we are not able to conclude anything regarding their relationship towards adherence.
The same is applied to the individuals that started their HIV therapy in the period of
recruitment of our sampled population; we are in absolutely no condition of saying that those
are more or less adherent.
Acknowledging that our patients are highly non-adherent to HAART and that there are
apparently no demographic or medication reasons for that we may ask how can we improve
our patient’s compliance to antiretroviral therapies so important to determine their own quality
of life and progression of disease? We reckon we might begin by developing a system of
continuous health assistance to this kind of population as a whole regardless of their
demographic or medication profile determinants. Education is in our point of view the tool
with which to guide our patients towards a positive behaviour and attitude in what their HIV
illness is concern.
Table 1: Distribution of race by sex. 
 Sex 
Male Female Total 
Race     n % n %    n   % 
Caucasian   236 45,2 100   19,2   336   64,4 
Non-caucasian    94 18,0  92   17,6   186   35,6 
Total   330 63,2 192   36,8 522 100,0 
n – number; % - percentual value; (IC 95%); N=522. 
Graphic 1: Distribution of age by group of 5 years. 
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Table 2: Distribution of Therapeutic Regimens during the recruitment period 
Therapeutic Regimens    n % 
2 NRTI + NNRTI 268 51,3 
2 NRTI + IP 153 29,3 
2 NRTI + 2 IP 49 9,4 
3 NRTI 17 3,3 
Others
( )
 35 6,7 
Total 522            100,0   
NRTI – Nucleoside Reverse Transcriptase Inhibitors; NNRTI - Non-Nucleoside Reverse Transcriptase 
Inhibitors; IP –Protease Inhibitors; ( ) – 2 NRTI + NtRTI (Nucleotide Analog Reverse Transcriptase 
Inhibitors), NRTI + IP + NtRTI, NRTI + NNRTI + NtRTI, NRTI + 2IP + NNRTI + NtRTI, 2IP + NNRTI 
+ NtRTI among others; n – number; % - percentual value; (IC 95%); N=522.  
Table 3: Number of pills per day distribution. 
Number of pills/day     n % 
2     10  1,9 
3 a 4   184 35,2 
5 a 6  108 20,7 
7 a 8    85 16,3 
9 a 10     55 10,5 
11 a 12    49  9,5 
13 a 14    31  5,9 
Total  522            100,0 
n – number; % - percentual value; (IC 95%); N=522.  
Table 4:  Number of takings per day distribution. 
Number of takings/day     n % 
1      6   1,1 
2   160 30,7 
3  232 44,4 
4     9   1,7 
5   115 22,0 
Total  522             100,0 
n – number; % - percentual value; (IC 95%); N=522.  
Graphic 2:  CMA Index Distribution as a measure of therapy obtaining adherence. 
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Table 5:  CMA Index distribution by gender. 
 Sex  
CMA Index
 
Male Female Total 
n(%)    
0.01, 0.49    20  (3,8)    22  (4,2)   42  (8,0) 
0.50, 0.89               97  (18,6)     73  (13,9)  170  (32,5) 
0.90, 0.94   38  (7,3)   22  (4,2)    60  (11,5) 
0.95, 0.99     82  (15,7)    40  (7,8)   122  (23,5) 
1.00, 1.49     93  (17,8)   35  (6,7)  128  (24,5) 
Total  330  (63,2)   192  (36,8)    522  (100,0) 
n – number; % - percentual value; (IC 95%); N=522. 
Table 6: CMA Index distribution by race. 
 Race  
CMA Index
 
Caucasian Non Caucasian Total 
n(%)    
0.01, 0.49    26  (5,0)    16  (3,1)   42  (8,1) 
0.50, 0.89               90  (17,2)     80  (15,2)  170  (32,5) 
0.90, 0.94   45  (8,6)   15  (2,9)    60  (11,5) 
0.95, 0.99     77  (14,7)    45  (8,6)   122  (23,3) 
1.00, 1.49     98  (18,8)   30  (5,7)  128  (24,5) 
Total  336  (64,4)   186  (35,6)    522  (100,0) 
n – number; % - percentual value; (IC 95%); N=522. 
Table 7: CMA Index distribution by age. 
 Age (Five years age group)   
CMA Index
 
20,29  30,39  40, 49  50, 59  60, 69  70, 79  Total 
n(%)        
0.01, 0.49               4 18 12 5 2 1   42   (8,0) 
0.50, 0.89  33 71 37 21 4 4 170  (32,6) 
0.90, 0.94  11 19 19 4 5 2    60  (11,5) 
0.95, 0.99  
10 53 32 17 7 3 
  122  (23,4) 
1.00, 1.49  10 49 35 21 12 1  128 (24,5) 
Total 68 210 135 68 30 11   522 (100,0) 
n – number; % - percentual value; (IC 95%); N=522. 
Table 8: CMA Index distribution by therapeutic regimen. 
 Therapeutic Regimen  
CMA Index
 2 NRTI + 
NNRTI 
2 NRTI 
+ IP 
2 NRTI 
+ 2IP 
3 NRTI Others( ) Total 
n(%)       
0.01, 0.49               20 11 7 3 1   42   (8,0) 
0.50, 0.89  85 52 16 3 14 170  (32,6) 
0.90, 0.94  30 21 3 2 4    60  (11,5) 
0.95, 0.99  
69 33 9 4 7 
  122  (23,4) 
1.00, 1.49  64 36 14 5 9  128 (24,5) 
Total 268 153 49 17 35   522 (100,0) 
NRTI – Nucleoside Reverse Transcriptase Inhibitors; NNRTI - Non-Nucleoside Reverse Transcriptase 
Inhibitors; IP –Protease Inhibitors; ( ) – 2 NRTI + NtRTI (Nucleotide Analog Reverse Transcriptase 
Inhibitors), NRTI + IP + NtRTI, NRTI + NNRTI + NtRTI, NRTI + 2IP + NNRTI + NtRTI, 2IP + NNRTI 
+ NtRTI among others; n – number; % - percentual value; (IC 95%); N=522.  
Table 9: CMA Index distribution by number of pills per day. 
 Number of pills /day  
CMA Index
 
2 3 a 4 5 a 6 7 a 8 9 a 10 11 a 12 13 a 14 Total 
n(%)         
0.01, 0.49               1 15 7 7 5 4 3   42   (8,0) 
0.50, 0.89  3 50 40 34 20 18 5 170  (32,6) 
0.90, 0.94  1 21 12 13 5 3 5    60  (11,5) 
0.95, 0.99  
2 49 25 17 10 11 8 
  122  (23,4) 
1.00, 1.49  3 49 24 14 15 13 9  128 (24,5) 
Total 10 184 108 85 50 49 30   522 (100,0) 
n – number; % - percentual value; (IC 95%); N=522. 
Table 10: CMA Index distribution by number of takings per day. 
 Number of takings /dia  
CMA Index
 
1 2 3 4 5 Total 
n(%)       
0.01, 0.49               1 15 17 1 8   42   (8,0) 
0.50, 0.89  1 55 70 2 42 170  (32,6) 
0.90, 0.94  - 17 23 1 19    60  (11,5) 
0.95, 0.99  
3 39 55 2 23 
  122  (23,4) 
1.00, 1.49  1 34 67 3 23  128 (24,5) 
Total 6 160 232 9 115   522 (100,0) 
n – number; % - percentual value; (IC 95%); N=522 
